learn Osteopontin
signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss
Search
forLearn
5 / 6 resultslearn Overview
learn sh-Polypeptide-7
learn Platelet-Derived Growth Factor Beta Polypeptide
learn Thymosin Beta 4
Research
5 / 1000+ results
research Teriflunomide: A Novel Oral Treatment for Relapsing Multiple Sclerosis
Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.
research Advances In The Mechanism And New Therapies Of Alopecia Areata
New treatments targeting the JAK signaling pathway, especially JAK inhibitors, show promise for alopecia areata.
research A Comparative Study of Regulations of Cell and Gene Therapy in the US, EU, and India
The US and EU lead in cell and gene therapy regulations with more approvals and clinical trials, while India is in early stages with fewer approvals and expedited processes.
research Alopecia Areata: Time for Position Statement to Include New Systemic Therapeutic Advances
New treatments for severe alopecia areata, especially JAK inhibitors, are recommended as first-line therapy.
research Artificial Hair: From the Dawn to Automatic Biofibre Hair Implant
Biofibre® hair implants are safe and effective for alopecia when proper procedures are followed, with high patient satisfaction.
Community Join
5 / 182 resultscommunity Mid 40s Fin only - 12 month update.
A user in their mid-40s shared a 12-month update on using finasteride for hair loss, showing significant improvement. They started seeing thicker hair and regrowth after 3 months, with no side effects noticed.
community EMA is re-examining Winlevi (clascoterone at lower concentration)
Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.
community Petition Alert: Let's Get PP405 Phase 3 Trials in Germany by 2026!
A user is advocating for Phase 3 trials of the hair loss treatment PP405 to be conducted in Germany, citing benefits like a diverse patient base and faster access for European patients. Despite skepticism about the petition's influence, the user believes it can demonstrate significant interest and potentially influence strategic decisions.
community Concerns about CosmeRNA safety mechanisms
Concerns about CosmeRNA safety mechanisms and potential side effects. Discussion includes comparisons to Fluridil and questions about nanoparticle specificity and siRNA stability.
community Hope Medicine announces HMI-115 phase II clinical trial for androgenetic alopecia in China
Hope Medicine's announcement of the HMI-115 Phase II clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.